文献速递糖尿病

以色列人群中钠-葡萄糖协同转运蛋白2抑制剂处方与发药差异——一项回顾性队列研究

Disparities in Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Prescription and Dispensing in the Israeli Population-A Retrospective Cohort Study.
PubMed 文献 · Diabetes Care · 2024-01-01

该研究为基于人群的回顾性队列研究,纳入2017至2023年符合SGLT2i治疗条件的2型糖尿病成人。在32,742例符合条件患者中仅53%被处方SGLT2i;多变量分析(以死亡为竞争风险校正)显示,处方延迟与年龄较大、阿拉伯或贝都因族裔、肿瘤、急性肾衰竭、跌倒、既往住院、尿路感染及痴呆相关;较短处方间隔与男性、中/高社会经济地位及居住于以色列中部或中间地区相关。结论认为即使在全民医保国家仍存在处方差异。

要点

  • 32,742例符合SGLT2i治疗条件的2型糖尿病成人中,仅53%被处方SGLT2i。
  • 校正死亡竞争风险后,处方延迟与年龄较大、阿拉伯或贝都因族裔、肿瘤、急性肾衰竭、跌倒、既往住院、尿路感染及痴呆相关。
  • 男性、中/高社会经济地位及居住于中部或中间地区与较短处方间隔相关。

核心结论

  • 即使在拥有全民医保的以色列,SGLT2i处方仍存在差异;解决这些差异需要改善医疗系统、教育及预警系统以克服循证干预的障碍。

研究设计与样本

  • 基于人群的回顾性队列研究,纳入2017至2023年符合SGLT2i治疗条件的2型糖尿病成人。
  • 主要结局为从初始符合条件至首次SGLT2i处方之间的时间。

主要发现

  • 在32,742例符合条件患者中,仅53%被处方SGLT2i。
  • 多变量分析(以死亡为竞争风险校正)显示,处方延迟与年龄较大、阿拉伯或贝都因族裔、肿瘤、急性肾衰竭、跌倒、既往住院、尿路感染及痴呆相关。
  • 较短处方间隔相关因素为男性、中/高社会经济地位及居住于以色列中部或中间地区。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe disparities in prescribing and dispensing sodium-glucose cotransporter 2 inhibitors (SGLT2i) in Israel. RESEARCH DESIGN AND METHODS: This was a population-based retrospective cohort study of adults with type 2 diabetes eligible for SGLT2i treatment from 2017 to 2023. The primary outcome was the time between initial eligibility and the first prescription of SGLT2i. RESULTS: Among 32,742 eligible patients, only 53% were prescribed SGLT2i. Multivariable analyses, adjusting for death as a competing risk, revealed delays in prescription were associated with older age, Arab or Bedouin ethnicity, neoplasms, acute kidney failure, falls, previous hospitalization, urinary tract infections, and dementia. Factors associated with shorter time intervals to prescription were sex (men), medium/high socioeconomic status, and residing in an intermediate or central area of Israel. CONCLUSIONS: Disparities in drug prescription exist, even in a country with universal health coverage. Addressing these disparities requires improvements in health care systems, education, and alert systems to overcome barriers to evidence-based interventions.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Weissman YL, Calvarysky B, Shochat T, et al. Disparities in Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Prescription and Dispensing in the Israeli Population-A Retrospective Cohort Study. Diabetes Care. 2024. PMID: 38377492. doi:10.2337/dc23-1652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。